Just type in #weightloss on any social media platform today and you'll be met with everything from intermittent fasting diets ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

The drugmaker launched a campaign supporting its weight loss medication Contrave, all backed by a cover version of Lesley Gore’s 1963 hit “You Don’t Own Me.” ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

Weight-loss drug stocks were catapulted into the spotlight in 2024, creating a lucrative, groundbreaking, and high-stakes ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...